The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival: A retrospective analysis

Transplantation

Volumn 89, Issue 4, 2010, Pages 472-479

  Kaloyannidis, Panayotis ^a   Yannaki, Evangelia ^a   Sakellari, Ioanna ^a   Bitzioni, Ekaterini ^a   Athanasiadou, Anastasia ^a   Mallouri, Despina ^a   Anagnostopoulos, Achilles ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

Allogeneic stem cell transplantation; Chelation; Desferrioxamine; Leukemia; Relapse

Indexed keywords

DEFEROXAMINE MESYLATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHELATION THERAPY; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRITINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, MYELOID; LYMPHOMA; MALE; MIDDLE AGED; PLATELET COUNT; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 77649166873     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c42944     Document Type: Article

References (39)

1. KumarL.Leukemia: Management ofrelapse after allogeneic bone marrow transplantation. J Clin Oncol 1994; 12: 1710.
2. Shaw BE, Russell NH. Treatment options for the management of acute leukemia relapsing following an allogeneic transplant. Bone Marrow Transplant 2008; 41: 495.
3. Farag SS, Bolwell BJ, Elder PJ, et al. High-dose busulfan, cyclophosph-amide, and etoposide does not improve outcomeof allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone Marrow Transplant 2005; 35: 653.
4. Mengarelli A, Iori A, Guglielmi C, et al. Standard versus alternative my-eloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002; 87: 52.
5. Alyea EP. Modulating graft-versus-host disease to enhance the graft-versus leukemia effect. Best Pract Res Clin Haematol 2008; 21: 239.
6. Bacigalupo A, Lamparelli T, Gualandi F, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia: A 10 year follow up of a randomized study. Blood 2001; 98: 3174.
7. de Lima M, Bonamino M, Vasconcelos Z, et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: High remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001; 27: 73.
8. Lutz C, Massenkeil G, Nagy M, et al. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lympho-blastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 805.
9. Hoke EM, Maylock CA, Shacter E. Desferal inhibits breast tumor growth and does not interfere with the tumorical activity of doxorubi-cin. Free Radic Biol Med 2005; 39: 403.
10. Hann HW, Stahlhut MW, Hann CL. Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 1990; 11: 566.
11. Leardi A, Caraglia M, Selleri C, et al. Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukemic cells. Br J Haematol 1998; 102: 746.
12. Becton D, Roberts B. Antileukemic effects of deferoxamine on human myeloid cell lines. Cancer Res 1998; 49: 4809.
13. Donfrancesco A, De Bernardi B, Carli M, et al. Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: Preliminary results. Italian Neuro-blastoma Cooperative Group Eur J Cancer 1995; 31A: 612.
14. Donfrancesco A, Deb G, Dominici G, et al. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990; 50: 4929.
15. Estrov Z, Tawa A, Wang XH, et al. In vivo and in vitro effects of defer-oxamine in neonatal acute leukaemia. Blood 1987; 69: 757.
16. Dezza L, Cazzola M, Danova M, et al. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth:Invitro and in vivo studies. Leukemia 1989; 3: 104.
17. Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 2002; 42: 267.
18. Maradei SC, Maiolino A, de Azevedo AM, et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009; 114: 1270.
19. Oblender M, Carpentieri U. Effects of iron, copper, and zink on the activity of ribonucleotide rectudase in normal and leukemic human lymphocytes. Anticancer Res 1990; 10: 123.
20. Nurtjahja-Tjendraputra E, Fu D, Phang JM, et al. Iron chelation regulates cyclin D1 expression via the proteasome: A linktoiron deficiency-mediated growth suppression. Blood 2007; 109: 4045.
21. Fu D, Richardson DR. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 2007; 110: 752.
22. Greene BT, Thorburn J, Willingham MC, et al. Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem 2002; 277: 25568.
23. Jiang Y, Xue ZH, Shen WZ, et al. Desferoxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1a that augments transcriptional activity of CCAAT/enhancer-binding protein-a. Leukemia 2005; 19: 1239.
24. Yan H, Peng ZG, Wu YL, et al. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica 2005; 90: 1607.
25. Guo M, Song LP, Jiang Y, et al. Hypoxia-mimetic agents desferrioxam-ine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor-1a independent mechanisms. Apoptosis 2006; 11: 67.
26. Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: Results from a randomized trial. J Natl Cancer Inst 2008; 100: 996.
27. Hileti D, Panayotidis P, Hoffbrand AV. Iron chelators induce apoptosis in proliferating cells. Br J Haematol 1995; 89: 181.
28. Vlachaki E, Ioannidou-Papagiannaki E, Tziomalos K, et al. Peripheral blood haematopoietic progenitor cells in patients with beta thalas-saemia major receiving desferrioxamine or deferiprone as chelation therapy. Eur J Haematol 2007; 78: 48.
29. Altes A, Remacha AF, Sureda A, et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 987.
30. de Witte T. The role of iron in patients after bone marrow transplantation. Blood Rev 2008; 22(suppl 2): S22.
31. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated prettransplantation serum ferritin in patients undergoing myeloabla-tive stem cell transplantation. Blood 2007; 109: 4586.
32. Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42: 799.
33. Armand P, Kim HT, Cutler CS, et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 28.
34. Schots R, Kaufman L, Van Riet I, et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003; 17: 1150.
35. Cooke KR, Hill GR, Gerbitz A, et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000; 70: 272.
36. Gallant T, Freedman MH, Vellend H, et al. Yersinia sepsis in patients with iron overload treated with deferoxamine. N Engl J Med 1986; 314: 1643.
37. Gaziev D, Giardini C, Angelucci E, et al. Intravenus chelation therapy during transplantation for thalassemia. Haematologica 1995; 80: 300.
38. Hoffbrand AV. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol 2005; 18: 290.
39. Kontoghiorghes GJ. Deferasirox: Uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin DrugSaf 2007; 6: 235.